Katharina Eikermann-Haerter1, Jeong Hyun Lee1, Nilufer Yalcin1, Esther S Yu1, Ali Daneshmand1, Ying Wei1, Yi Zheng1, Anil Can1, Buse Sengul1, Michel D Ferrari1, Arn M J M van den Maagdenberg1, Cenk Ayata2. 1. From the Neurovascular Research Laboratory, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown (K.E.-H., J.H.L., N.Y., E.S.Y., A.D., Y.W., Y.Z., A.C., B.S., C.A.); Department of Neurology (M.D.F., A.M.J.M.v.d.M), and Department of Human Genetics, Leiden University Medical Centre, The Netherlands (A.M.J.M.v.d.M); and Stroke Service and Neuroscience Intensive Care Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston (C.A.). 2. From the Neurovascular Research Laboratory, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Charlestown (K.E.-H., J.H.L., N.Y., E.S.Y., A.D., Y.W., Y.Z., A.C., B.S., C.A.); Department of Neurology (M.D.F., A.M.J.M.v.d.M), and Department of Human Genetics, Leiden University Medical Centre, The Netherlands (A.M.J.M.v.d.M); and Stroke Service and Neuroscience Intensive Care Unit, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston (C.A.). cayata@partners.org.
Abstract
BACKGROUND AND PURPOSE: Migraine with aura is an established stroke risk factor, and excitatory mechanisms such as spreading depression (SD) are implicated in the pathogenesis of both migraine and stroke. Spontaneous SD waves originate within the peri-infarct tissue and exacerbate the metabolic mismatch during focal cerebral ischemia. Genetically enhanced SD susceptibility facilitates anoxic depolarizations and peri-infarct SDs and accelerates infarct growth, suggesting that susceptibility to SD is a critical determinant of vulnerability to ischemic injury. Because chronic treatment with migraine prophylactic drugs suppresses SD susceptibility, we tested whether migraine prophylaxis can also suppress ischemic depolarizations and improve stroke outcome. METHODS: We measured the cortical susceptibility to SD and ischemic depolarizations, and determined tissue and neurological outcomes after middle cerebral artery occlusion in wild-type and familial hemiplegic migraine type 1 knock-in mice treated with vehicle, topiramate or lamotrigine daily for 7 weeks or as a single dose shortly before testing. RESULTS: Chronic treatment with topiramate or lamotrigine reduced the susceptibility to KCl-induced or electric stimulation-induced SDs as well as ischemic depolarizations in both wild-type and familial hemiplegic migraine type 1 mutant mice. Consequently, both tissue and neurological outcomes were improved. Notably, treatment with a single dose of either drug was ineffective. CONCLUSIONS: These data underscore the importance of hyperexcitability as a mechanism for increased stroke risk in migraineurs, and suggest that migraine prophylaxis may not only prevent migraine attacks but also protect migraineurs against ischemic injury.
BACKGROUND AND PURPOSE:Migraine with aura is an established stroke risk factor, and excitatory mechanisms such as spreading depression (SD) are implicated in the pathogenesis of both migraine and stroke. Spontaneous SD waves originate within the peri-infarct tissue and exacerbate the metabolic mismatch during focal cerebral ischemia. Genetically enhanced SD susceptibility facilitates anoxic depolarizations and peri-infarct SDs and accelerates infarct growth, suggesting that susceptibility to SD is a critical determinant of vulnerability to ischemic injury. Because chronic treatment with migraine prophylactic drugs suppresses SD susceptibility, we tested whether migraine prophylaxis can also suppress ischemic depolarizations and improve stroke outcome. METHODS: We measured the cortical susceptibility to SD and ischemic depolarizations, and determined tissue and neurological outcomes after middle cerebral artery occlusion in wild-type and familial hemiplegic migraine type 1 knock-in mice treated with vehicle, topiramate or lamotrigine daily for 7 weeks or as a single dose shortly before testing. RESULTS: Chronic treatment with topiramate or lamotrigine reduced the susceptibility to KCl-induced or electric stimulation-induced SDs as well as ischemic depolarizations in both wild-type and familial hemiplegic migraine type 1 mutant mice. Consequently, both tissue and neurological outcomes were improved. Notably, treatment with a single dose of either drug was ineffective. CONCLUSIONS: These data underscore the importance of hyperexcitability as a mechanism for increased stroke risk in migraineurs, and suggest that migraine prophylaxis may not only prevent migraine attacks but also protect migraineurs against ischemic injury.
Authors: Jan Lewis Brandes; Joel R Saper; Merle Diamond; James R Couch; Donald W Lewis; Jennifer Schmitt; Walter Neto; Stefan Schwabe; David Jacobs Journal: JAMA Date: 2004-02-25 Impact factor: 56.272
Authors: Verneri Anttila; Bendik S Winsvold; Padhraig Gormley; Tobias Kurth; Francesco Bettella; George McMahon; Mikko Kallela; Rainer Malik; Boukje de Vries; Gisela Terwindt; Sarah E Medland; Unda Todt; Wendy L McArdle; Lydia Quaye; Markku Koiranen; M Arfan Ikram; Terho Lehtimäki; Anine H Stam; Lannie Ligthart; Juho Wedenoja; Ian Dunham; Benjamin M Neale; Priit Palta; Eija Hamalainen; Markus Schürks; Lynda M Rose; Julie E Buring; Paul M Ridker; Stacy Steinberg; Hreinn Stefansson; Finnbogi Jakobsson; Debbie A Lawlor; David M Evans; Susan M Ring; Markus Färkkilä; Ville Artto; Mari A Kaunisto; Tobias Freilinger; Jean Schoenen; Rune R Frants; Nadine Pelzer; Claudia M Weller; Ronald Zielman; Andrew C Heath; Pamela A F Madden; Grant W Montgomery; Nicholas G Martin; Guntram Borck; Hartmut Göbel; Axel Heinze; Katja Heinze-Kuhn; Frances M K Williams; Anna-Liisa Hartikainen; Anneli Pouta; Joyce van den Ende; Andre G Uitterlinden; Albert Hofman; Najaf Amin; Jouke-Jan Hottenga; Jacqueline M Vink; Kauko Heikkilä; Michael Alexander; Bertram Muller-Myhsok; Stefan Schreiber; Thomas Meitinger; Heinz Erich Wichmann; Arpo Aromaa; Johan G Eriksson; Bryan Traynor; Daniah Trabzuni; Elizabeth Rossin; Kasper Lage; Suzanne B R Jacobs; J Raphael Gibbs; Ewan Birney; Jaakko Kaprio; Brenda W Penninx; Dorret I Boomsma; Cornelia van Duijn; Olli Raitakari; Marjo-Riitta Jarvelin; John-Anker Zwart; Lynn Cherkas; David P Strachan; Christian Kubisch; Michel D Ferrari; Arn M J M van den Maagdenberg; Martin Dichgans; Maija Wessman; George Davey Smith; Kari Stefansson; Mark J Daly; Dale R Nyholt; Daniel Chasman; Aarno Palotie Journal: Nat Genet Date: 2013-06-23 Impact factor: 38.330
Authors: Arn M J M van den Maagdenberg; Daniela Pietrobon; Tommaso Pizzorusso; Simon Kaja; Ludo A M Broos; Tiziana Cesetti; Rob C G van de Ven; Angelita Tottene; Jos van der Kaa; Jaap J Plomp; Rune R Frants; Michel D Ferrari Journal: Neuron Date: 2004-03-04 Impact factor: 17.173
Authors: David Y Chung; Homa Sadeghian; Tao Qin; Sevda Lule; Hang Lee; Fahri Karakaya; Stacy Goins; Fumiaki Oka; Mohammad A Yaseen; Thijs Houben; Else A Tolner; Arn M J M van den Maagdenberg; Michael J Whalen; Sava Sakadžic; Cenk Ayata Journal: Cereb Cortex Date: 2019-03-01 Impact factor: 5.357
Authors: Jens P Dreier; Martin Fabricius; Cenk Ayata; Oliver W Sakowitz; C William Shuttleworth; Christian Dohmen; Rudolf Graf; Peter Vajkoczy; Raimund Helbok; Michiyasu Suzuki; Alois J Schiefecker; Sebastian Major; Maren Kl Winkler; Eun-Jeung Kang; Denny Milakara; Ana I Oliveira-Ferreira; Clemens Reiffurth; Gajanan S Revankar; Kazutaka Sugimoto; Nora F Dengler; Nils Hecht; Brandon Foreman; Bart Feyen; Daniel Kondziella; Christian K Friberg; Henning Piilgaard; Eric S Rosenthal; M Brandon Westover; Anna Maslarova; Edgar Santos; Daniel Hertle; Renán Sánchez-Porras; Sharon L Jewell; Baptiste Balança; Johannes Platz; Jason M Hinzman; Janos Lückl; Karl Schoknecht; Michael Schöll; Christoph Drenckhahn; Delphine Feuerstein; Nina Eriksen; Viktor Horst; Julia S Bretz; Paul Jahnke; Michael Scheel; Georg Bohner; Egill Rostrup; Bente Pakkenberg; Uwe Heinemann; Jan Claassen; Andrew P Carlson; Christina M Kowoll; Svetlana Lublinsky; Yoash Chassidim; Ilan Shelef; Alon Friedman; Gerrit Brinker; Michael Reiner; Sergei A Kirov; R David Andrew; Eszter Farkas; Erdem Güresir; Hartmut Vatter; Lee S Chung; K C Brennan; Thomas Lieutaud; Stephane Marinesco; Andrew Ir Maas; Juan Sahuquillo; Markus A Dahlem; Frank Richter; Oscar Herreras; Martyn G Boutelle; David O Okonkwo; M Ross Bullock; Otto W Witte; Peter Martus; Arn Mjm van den Maagdenberg; Michel D Ferrari; Rick M Dijkhuizen; Lori A Shutter; Norberto Andaluz; André P Schulte; Brian MacVicar; Tomas Watanabe; Johannes Woitzik; Martin Lauritzen; Anthony J Strong; Jed A Hartings Journal: J Cereb Blood Flow Metab Date: 2016-01-01 Impact factor: 6.200
Authors: Paul Fischer; Kazutaka Sugimoto; David Y Chung; Isra Tamim; Andreia Morais; Tsubasa Takizawa; Tao Qin; Carlos A Gomez; Frieder Schlunk; Matthias Endres; Mohammad A Yaseen; Sava Sakadzic; Cenk Ayata Journal: J Cereb Blood Flow Metab Date: 2020-09-16 Impact factor: 6.200